Venture
Asklepios BioPharmaceutical, Inc.
Latest Form D 2019-05-29- CIK 1352189
- State NC
- Biotechnology
- 1 Form D offering since 2019-05-29
- Total sold
- $200M
- across its one offering
- Rounds
- 1
- Form D offerings since 2019-05-29
- Latest round
- $200M
- 2019-05-29 · 021-340600
- Investors
- 33
- on the latest round
Connected
named in its Form D filingsOfferings · since 2019-05-291 Form D offeringExemptions506(b)People · Item 3Sheila Mikhail + 8 moreInvestors · dashboardInferred investors
Asklepios BioPharmaceutical, Inc.CIK 1352189
Round timeline
amount sold · by first filed2019-05-29 · $200M
- 2019-05-29$200M021-340600
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($200M)
Form D offerings
One line per offering, amendments folded in, newest first
| File | First filed | Latest | Sought | Sold | Investors | Exemptions |
|---|---|---|---|---|---|---|
| 021-340600 | First filed2019-05-29 | Latest2019-05-29 | Sought$200M | Sold$200M | Investors33 | Exemptions506(b) |
Who backs Asklepios BioPharmaceutical, Inc., inferred from co-filings, and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2019-05-29
| Name | Relationship | Clarification |
|---|---|---|
| Sheila Mikhail | RelationshipExecutive Officer, Director | ClarificationCEO, Treasurer and Secretary |
| Richard Samulski | RelationshipExecutive Officer, Director | ClarificationPresident and Chief Science Officer |
| William Hawkins | RelationshipDirector | Clarification— |
| Javier Garcia | RelationshipDirector | Clarification— |
| Jon Salveson | RelationshipDirector | Clarification— |
| John Schilling | RelationshipDirector | Clarification— |
| Katherine Wood | RelationshipDirector | Clarification— |
| Fred Cohen | RelationshipDirector | Clarification— |
| Timothy Ferguson | RelationshipExecutive Officer | ClarificationAssistant Secretary |
Facts
As its latest Form D states them
- Industry
- Biotechnology
- State
- North Carolina (NC)
- Exemptions
- Rule 506(b)
- First filed
- 2019-05-29
- Latest filing
- 2019-05-29
- Minimum investment
- $101K
Who backs Asklepios BioPharmaceutical, Inc.
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
- Inferred investors — the funds and firms behind it, from co-filings and shared people
- Every Form D and amendment as filed, with what each one stated
- Its rounds in sequence: the gap between them and whether they grew
- Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)
See plansExternal link: SEC Filings ↗